Difficulty: Medium
Average Score: 70%
Practice
Methylxanthines for the treatment of broncho-pulmonary dysplasia (BPD) have the following effects EXCEPT
Correct answer
D
Rationale
In the context of pediatric nursing, understanding the effects of methylxanthines on broncho-pulmonary dysplasia (BPD) is crucial for safe and effective patient care. Methylxanthines like caffeine and theophylline are commonly used in neonates with BPD to improve respiratory function.
The correct answer, option D, states that methylxanthines do not increase pulmonary vascular resistance (PVR). This is accurate because methylxanthines actually have a vasodilatory effect on the pulmonary vasculature, reducing PVR and improving oxygenation.
Option A, increasing respiratory drive, is a known effect of methylxanthines. They stimulate the respiratory center in the brain, leading to increased respiratory effort. Option B, decreasing apnea, is another recognized effect as methylxanthines help in reducing the frequency of apneic episodes in infants with BPD.
Option C, improving diaphragmatic contractility, is an incorrect statement. Methylxanthines primarily work by stimulating the central nervous system and respiratory centers rather than directly affecting diaphragmatic contractility.
Educationally, this question highlights the pharmacological effects of methylxanthines in the treatment of BPD. It reinforces the importance of understanding how medications impact different physiological processes in pediatric patients. This knowledge is essential for nurses to monitor for both therapeutic effects and potential adverse reactions when caring for infants with respiratory conditions like BPD.
The correct answer, option D, states that methylxanthines do not increase pulmonary vascular resistance (PVR). This is accurate because methylxanthines actually have a vasodilatory effect on the pulmonary vasculature, reducing PVR and improving oxygenation.
Option A, increasing respiratory drive, is a known effect of methylxanthines. They stimulate the respiratory center in the brain, leading to increased respiratory effort. Option B, decreasing apnea, is another recognized effect as methylxanthines help in reducing the frequency of apneic episodes in infants with BPD.
Option C, improving diaphragmatic contractility, is an incorrect statement. Methylxanthines primarily work by stimulating the central nervous system and respiratory centers rather than directly affecting diaphragmatic contractility.
Educationally, this question highlights the pharmacological effects of methylxanthines in the treatment of BPD. It reinforces the importance of understanding how medications impact different physiological processes in pediatric patients. This knowledge is essential for nurses to monitor for both therapeutic effects and potential adverse reactions when caring for infants with respiratory conditions like BPD.